

Rockledge Drive, Room 4106, Bethesda, Maryland 20892, (301) 435-1786.

Name of SEP: Biological and Physiological.

Date: December 10, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6178, Telephone Conference.

Contact Person: Dr. Nancy Pearson, Scientific Review Administrator, 6701 Rockledge Drive, Room 6178, Bethesda, Maryland 20892, (301) 435-1047.

Name of SEP: Biological and Physiological.

Date: December 11, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6178, Telephone Conference.

Contact Person: Dr. Nancy Pearson, Scientific Review Administrator, 6701 Rockledge Drive, Room 6178, Bethesda, Maryland 20892, (301) 435-1047.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Behavioral and Neurosciences.

Date: January 18, 1998.

Time: 8:30 a.m.

Place: The Williard Hotel, Washington, DC.

Contact Person: Dr. David Simpson, Scientific Review Administrator, 6701 Rockledge Drive, Room 5192, Bethesda, Maryland 20892, (301) 435-1278.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: December 2, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-32092 Filed 12-8-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Therapeutic Uses of Blood Vessel Growth Promoting Peptides Including Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF) for Cardiovascular Disease and Conditions Such as Myocardial Ischemia

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a domestic exclusive license to practice the inventions embodied in the patent referred to below to Collateral Therapeutics of San Diego, California. The patent rights in these inventions have been assigned to the government of the United States of America. The patent to be licensed is: "Method To Foster Myocardial Blood Vessel Growth And Improve Blood Flow To The Heart", U.S. Patent Application Serial No. 07/799,830 filed November 27, 1991, which issued as U.S. Patent No. 5,244,460 on September 14, 1993.

DATES: Only written comments and/or applications for a license which are received by NIH on or before February 9, 1998 will be considered.

ADDRESSES: Requests for a copy of this patent, inquiries, comments, and other materials relating to the contemplated license should be directed to: J. Peter Kim, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7056, ext. 264; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The present invention relates to improvements in the treatment of diseases, and more particularly to procedures and compositions used to foster myocardial blood vessel growth

and improve blood flow to the heart. The present invention provides a method for facilitating in a damaged heart or a heart in need of improved circulation the growth of cardiac blood vessels while reducing the risk of undesired vascularization in other areas of the body. The method comprises: (a) Inserting a catheter into a coronary artery and providing an infusion port accessible to the administration of coronary drug injections; (b) injecting an effective amount of a blood vessel growth promoting peptide into the heart; and (c) periodically repeating such injection on subsequent days until improved cardiac blood flow has been obtained. The subject invention may be applied to treating cardiovascular disease and conditions including myocardial ischemia and atherosclerosis of the coronary arteries. Such a therapy can potentially be used to partially or completely replace blocked coronary arteries with new blood vessels without affecting the degree of vascularity in the area of the body.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Copies of the subject issued patent are available upon request.

Dated: December 1, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-32088 Filed 12-8-97; 8:45 am]

BILLING CODE 4140-01-M